Art

J-GLOBAL ID：201802228609822401   Reference number：18A1071054

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension

重症肺動脈高血圧症患者におけるトレプロスチニルからセレキシパグへの成功した移行【JST・京大機械翻訳】

Author (7)： Furukawa Asuka (Pulmonary Hypertension Center, International University of Health and Welfare Mita Hospital, Tokyo, Japan) ,  Tamura Yuichi (Pulmonary Hypertension Center, International University of Health and Welfare Mita Hospital, Tokyo, Japan) ,  Iwahori Hiroya (Department of Cardiology, International University of Health and Welfare Mita Hospital, Tokyo, Japan) ,  Goto Masato (Department of Cardiology, International University of Health and Welfare Mita Hospital, Tokyo, Japan) ,  Ohashi Narutaka (Department of Cardiology, International University of Health and Welfare Mita Hospital, Tokyo, Japan) ,  Okabe Teruo (Department of Cardiology, International University of Health and Welfare Mita Hospital, Tokyo, Japan) ,  Kawamura Akio (Department of Cardiology, International University of Health and Welfare Mita Hospital, Tokyo, Japan)
Material： BMC Pulmonary Medicine (Web)
Volume： 17  Issue： 1  Page： 135  Publication year： 2017 
JST Material Number： U7449A  ISSN： 1471-2466  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Background In this report, we ...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1071054&from=J-GLOBAL&jstjournalNo=U7449A") }}

Thesaurus term： combination therapy ,  therapy ,  oral administration ,  Exercise tolerance ,  woman ,  motor capacity ,  self administration ,  subcutaneous administration ,  pulmonary hypertension ,  hemodynamics ,  *patient ,  enzyme inhibitor ,  antihormone ,  prostaglandin
Semi thesaurus term： 重症 , 【Automatic Indexing@JST】

Author keywords (4)： Pulmonary hypertension ,  Medical therapy ,  Combination therapy ,  Prostanoid

JST classification (2)： Clinical application of vasoactive drugs and hypotensive drugs  (GW07050U) ,  Drug therapy(=pharmacotherapy)for cardiovascular system diseases  (GJ05020M)

Substance index (3)： Tadalafil ,  Selexipag ,  Treprostinil

Reference (8)：

• Eur Respir J; Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study; O Sitbon, X Jaïs, L Savale, V Cottin, E Bergot, EA Macari, H Bouvaist, C Dauphin, F Picard, S Bulifon, D Montani, M Humbert, G Simonneau; 43; 6; 2014; 1691-1697; 10.1183/09031936.00116313; CR1;
• N Engl J Med; Selexipag for the treatment of pulmonary arterial hypertension; O Sitbon, R Channick, KM Chin, A Frey, S Gaine, N Galiè, HA Ghofrani, MM Hoeper, IM Lang, R Preiss, LJ Rubin, L Di Scala, V Tapson, I Adzerikho, J Liu, O Moiseeva, X Zeng, G Simonneau, VV McLaughlin, GRIPHON Investigators; 373; 26; 2015; 2522-2533; 10.1056/NEJMoa1503184; CR2;
• Eur J Pharmacol; Comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries; C Fuchikami, K Murakami, K Tajima, J Homan, K Kosugi, K Kuramoto, M Oka, KA Kuwano; 795; 2017; 75-83; 10.1016/j.ejphar.2016.11.057; CR3;
• J Cardiovasc Pharmacol; Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers; K Laliberte, C Arneson, R Jeffs, T Hunt, M Wade; 44; 2; 2004; 209-214; 10.1097/00005344-200408000-00010; CR4;
• Pharmacology; Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects; S Bruderer, N Hurst, P Kaufmann, J Dingemanse; 94; 3-4; 2014; 148-156; 10.1159/000367630; CR5;

Terms in the title (7)： 重症 ,  肺動脈高血圧症 ,  患者 ,  トレプロスチニル ,  セレキシパグ ,  成功 ,  移行